Content area
Abstract
Highlights
* Mismatch between vaccine and circulating strains impairs vaccine immunogenicity. * Intradermal route (ID) of administration has been shown to enhance immunogenicity. * Intanza®15μg is the first licensed ID inactivated split-virion influenza vaccine. * We evaluated its ability to elicit antibody response against H3N2 circulating viruses. * Intanza®15μg elicited broader antibody responses than IM vaccine in the elderly.
Details
Title
Intanza?15mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses
Author
Ansaldi, Filippo; Canepa, Paola; Ceravolo, Antonella; Valle, Laura; de Florentiis, Daniela; Oomen, Raymond; Vogel, Frederick R; Denis, Martine; Samson, Sandrine I; Icardi, Giancarlo
Pages
2908-2913
Publication year
2012
Publication date
Apr 16, 2012
ISSN
0264410X
e-ISSN
18732518
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
1618950720
Copyright
Copyright Elsevier Limited Apr 16, 2012